Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: A replay of the conference call will be available within two hours of the call's completion and will remain accessible for two weeks by dialing 800-839-8389 and entering access code 4757982. About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of“Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.
S.-based manufacturing; and its Established Brands business. For more information, visit .
Investor Relations Contact: Lisa M. Wilson, In-Site Communications, Inc. 212-452-2793 .
.. SOURCE: ANI Pharmaceuticals, Inc.
MENAFN30102024004107003653ID1108835308 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contai.
